$Novavax (NVAX.US)$ surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with $Sanofi (SNY.US)$. The firm also posted a quarterly loss $1.05 a share Friday. The company also lifted its going-concern notice that was issued over a year ago.
$諾瓦瓦克斯醫藥 (NVAX.US)$ 在這家疫苗生產商表示已與之達成價值高達14億美元的許可協議後，該疫苗飆升 $賽諾菲安萬特 (SNY.US)$。該公司週五還公佈了每股1.05美元的季度虧損。該公司還取消了一年多前發佈的持續經營通知。
The company said overnight that it would jointly commercialize its Covid-19 vaccine worldwide with Sanofi. The French healthcare company will get a sole license to combine the treatment with its flu vaccine.
該公司隔夜表示，將與賽諾菲共同在全球範圍內將其Covid-19疫苗商業化。這家法國醫療保健公司將獲得將該療法與流感疫苗結合的唯一許可。
Sanofi will take a minority stake of less than 5% in Novavax.
賽諾菲將收購Novavax不到5％的少數股權。